Adaptive Clinical Research Inc — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$29,798	7
2024	Research	$414,775	54
2023	Research	$1,945,559	65
2022	Research	$2,239,714	46
2021	Research	$186,969	8

Breakdown

Who paid Research payments · program years 2021–2025

ITI, Inc. $2,476,323 61 payments
Teva Pharmaceuticals USA, Inc. $2,302,867 109 payments
Sumitomo Pharma America, Inc. $23,490 6 payments
Eli Lilly and Company $13,900 1 payment
Hoffmann-La Roche Limited $225 2 payments
AbbVie, Inc. $10 1 payment

Studies the money was for Research payments · program years 2021–2025

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $2,476,323 61 payments
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $2,302,867 109 payments
An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia $18,208 5 payments
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $13,900 1 payment
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication $5,282 1 payment
Acute Schizophrenia Study $225 2 payments
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $10 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.